Completed PHASE3 INTERVENTIONAL NCT00040235

Magnesium Effects in Apheresis

Citrate Effects and Role of Prophylactic Magnesium Administration During Large-Volume Leukapheresis

Sponsor: National Institutes of Health Clinical Center (CC)

Conditions Healthy

Interventions magnesium

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Jun 30, 2002 Completion: Feb 29, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00040235, this PHASE3 trial focuses on Healthy and remains completed. Sponsored by National Institutes of Health Clinical Center (CC), it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institutes of Health Clinical Center (CC)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States